2026 Biotech Approval Scorecard: 10 Approvals, 2 Franchises

2026 is shaping up as the biggest approval year biotech has seen in a long time. Between July 1 and August 19 the FDA cleared ten new drugs or label expansions: the first mRNA flu shot, the first oncolytic virus for melanoma, the first CELMoD for multiple myeloma, the first gene therapy for GSDIa, a pediatric CRISPR expansion, and the second tau PET tracer ever approved. Investors are treating each one as a finish line. That is the mistake. The first 90 days after approval decide whether a drug becomes a franchise or a write-down, and applying that lens to the 2026 class produces an uncomfortable scorecard: two franchises, both owned by mega-caps where they barely move the stock, and zero pure-play winners so far.

The 90-Day Scorecard, Applied

The framework has four checkpoints. The label: what did the FDA approve versus what the company asked for. Pricing and PBM positioning: a six-figure price triggers formulary fights, and a lowball price admits the data is weak. Distribution: can the drug reach patients at all. First scripts: the Day 60 to 90 prescription data that sets the two-year revenue model. Most of the 2026 class has not cleared checkpoint one, so these are ranked on the setup, not the scripts.

The Two Franchises

Zenbexus (iberdomide), Bristol Myers Squibb, approved August 13. The franchise candidate in the class and the first CELMoD on the market in myeloma. EXCALIBER-RRMM randomized 939 patients; the MRD analysis on the first 420 showed a minimal residual disease-negative complete response in 41% of the ZDd arm versus 21% for the DVd control (p<0.0001), the first myeloma approval based on MRD negativity rather than progression-free survival. This is BMY engineering the successor to Revlimid and Pomalyst, the franchise that anchored its oncology business for a decade. The catch is the label: boxed warnings for neutropenia (90.2% of patients) and infections (78.9%), plus accelerated approval contingent on a confirmatory progression-free survival readout. BMY at $67.92 is a $129 billion company fighting the Eliquis and Opdivo patent cliff, so Zenbexus is a counterweight, not a stock mover. The franchise is real; the tradable move is not.

Fabhalta (iptacopan), Novartis, traditional approval July 17. Fabhalta converted from accelerated to traditional approval in IgA nephropathy, the first of the new IgAN entrants to cross that line. Traditional approval means no confirmatory-trial asterisk hanging over the label, and it is a genuine competitive weapon against Vera’s Trutakna and Otsuka’s Voyxact, which still carry accelerated status. The offset is a REMS requirement for encapsulated-bacteria infections, and the fact that Novartis at $159.98 is a $300 billion-plus company where IgAN is one line item in a $50 billion-plus revenue base. Franchise for the product line, footnote for the share price.

The Three Bets

Trutakna (atacicept), Vera Therapeutics, accelerated approval July 7. The pure-play question mark of the class. Trutakna is the first dual BAFF/APRIL inhibitor for IgAN, with a 46% reduction from baseline (42% versus placebo) in proteinuria in ORIGIN 3, but it enters sixth in a crowded field and carries an accelerated-approval label. Vera at $35.28 is a $2.54 billion company whose entire thesis now rests on the ORIGIN 3 confirmatory eGFR readout, pulled forward to this quarter after Vera aligned with the FDA on an earlier analysis. If the eGFR data shows slowed kidney-function decline, Vera files a supplemental BLA in Q4 and closes the regulatory gap with Fabhalta. If it misses, the accelerated approval is at risk and Vera re-rates hard. This is the single highest-conviction binary event in the class, and it lands within weeks. See ORIGIN 3 on ClinicalTrials.gov.

Tudriqev (RP1), Replimune, accelerated approval August 6. The first oncolytic virus approved for melanoma, after two complete response letters. IGNYTE produced a 24.2% objective response rate with a 14.1-month median duration of response in patients who progressed on anti-PD-1 therapy, roughly half of the estimated 105,000 new US melanoma cases each year. Replimune at $15.80 is a $1.49 billion company that just raised financing to fund the launch. The two binary risks are launch execution against entrenched checkpoint regimens and the confirmatory IGNYTE-3 readout in 2027. A bet, not a franchise.

Genglycos (DTX401), Ultragenyx, accelerated approval August 19. The first gene therapy for the rare disease GSDIa, cutting daily cornstarch requirements (p<0.001) in the Phase 3 GlucoGene study. Ultragenyx at $26.46 is a $2.61 billion company that earned a priority review voucher worth roughly $100 million, the most tangible near-term asset. But GSDIa is 1,500 to 2,500 US patients, and the accelerated approval requires confirmatory data from a Disease Monitoring Program. A platform validation for Ultragenyx’s AAV8 engine, not a revenue engine.

The Five Footnotes

mFLUVISA, Moderna, August 5. The first mRNA flu vaccine, with 26.6% relative efficacy over standard-dose shots. Moderna guided zero 2026 revenue from it and the first real season is 2027-28. The stock nearly tripled anyway: on August 19 Merck and Moderna reported that intismeran plus KEYTRUDA met the recurrence-free survival and distant metastasis-free survival endpoints in the Phase 3 INTerpath-001 trial in resected melanoma, the first positive Phase 3 for an individualized mRNA cancer therapy (Merck press release). Moderna at $158.83 is a $63 billion company re-rated on the cancer vaccine, not the flu shot. mFLUVISA is platform validation and a footnote.

Lytenava (bevacizumab-vikg), Outlook Therapeutics, July 24. The Lytenava, the first FDA-approved ophthalmic bevacizumab, cleared on its fourth attempt. Outlook at $0.64 is a $155 million company that has not yet launched in the US (planned before end of 2026) and just priced a $55 million offering at $0.99 with warrants, diluting shareholders by 55.5 million shares. The stock is down roughly 35% since approval, competing against compounded off-label bevacizumab at about $50 a dose. The clearest footnote in the class.

Pasatru (garetosmab), Regeneron, August 19. The first drug to show a 90% reduction in new heterotopic ossification lesions in FOP, an 800-patient disease (Pasatru approval). Regeneron at $833.56 is an $89 billion company where Pasatru will be immaterial, and Mirum’s oral zilurgisertib, with a September 26 PDUFA, is weeks away. A medical win and an investing footnote.

Casgevy pediatric expansion, Vertex, July 1. The first CRISPR therapy cleared for children as young as 2, adding roughly 5,500 eligible patients. The commercial story is now accelerating: Casgevy revenue hit $76.4 million in Q2 2026, up 150% year over year and 75% sequentially, and Vertex raised full-year guidance to $13.1 billion with $500 million-plus expected from Casgevy and Journavx combined. Vertex at $552.85 is a $120 billion-plus company where Casgevy is still a rounding error, and the ramp remains gated by authorized treatment centers and a $2.2 million list price. A real franchise, but the Casgevy 18-month scorecard still frames it as a decade-long build, not a launch pop.

TAUKLARIFY (florquinitau F 18), Lantheus, August 14. The second tau PET tracer for Alzheimer’s, beating Lilly’s Tauvid on accuracy (AUC 0.93 versus 0.86). Lantheus at $100.87 is already sold to Curium at $102.50 cash plus CVRs, so the approval is merger-arbitrage math, not a catalyst. Good science, no trade.

The Read-Across

The 2026 class keeps teaching the same lesson. Every franchise in the class belongs to a mega-cap where the drug is a rounding error: Zenbexus at BMY, Fabhalta at Novartis, Casgevy at Vertex, Pasatru at Regeneron. The approval matters to the product line, not the share price. The pure plays are where the money moves, and all four of them, Vera, Replimune, Ultragenyx, and Outlook, are still unproven or stalling. The market pays for the launch and the confirmatory trial, not the approval pop: Trutakna popped on July 7 and is flat a month later; Lytenava faded 35%. The class confirms what the IBTROZI one-year tracking and the Leqembi three-year review already showed: approval is the starting line, not the finish line.

Names to Keep Tracking

• Vera: the ORIGIN 3 eGFR readout this quarter is the make-or-break.
• Replimune: launch execution plus IGNYTE-3.
• Moderna: intismeran regulatory filing and the overall survival follow-up.
• Ultragenyx: Genglycos confirmatory data plus the September 19 UX111 PDUFA.

These four still carry tradable catalysts the 2026 class has not yet resolved.

The Verdict

The 2026 approval class produced two genuine franchises, Zenbexus and Fabhalta, and both are immaterial to their mega-cap owners. The tradable story is not the approvals; it is the confirmatory data and launch numbers still ahead for the pure plays. Own Vera ahead of the ORIGIN 3 readout at a 1% to 2% position size, and leave the rest of the class alone until the first script data lands.